临床医药实践
臨床醫藥實踐
림상의약실천
PROCEEDING OF CLINICAL MEDICINE
2015年
6期
406-408
,共3页
恶性胸/腹腔积液%重组改构人肿瘤坏死因子%顺铂
噁性胸/腹腔積液%重組改構人腫瘤壞死因子%順鉑
악성흉/복강적액%중조개구인종류배사인자%순박
malignant pleural/peritoneal effusion%recombinant human tumor necrosis factor%cisplatin
目的:探讨重组改构人肿瘤坏死因子( rmhTNF)对恶性胸/腹腔积液的治疗作用。方法:观察56例恶性胸/腹腔积液的患者,随机分为TNF组(用rmhTNF胸/腹腔内注入治疗)和DDP组(用顺铂胸/腹腔内注入治疗),观察两组疗效、生存质量变化及不良反应情况。结果:TNF组总有效率明显高于DDP组(P<0.05);TNF组生存质量改善率明显高于DDP组(P<0.05);TNF组的不良反应发生率明显低于DDP组。结论:rmhTNF具有显著的消除胸/腹腔积液的作用,疗效明显优于DDP。
目的:探討重組改構人腫瘤壞死因子( rmhTNF)對噁性胸/腹腔積液的治療作用。方法:觀察56例噁性胸/腹腔積液的患者,隨機分為TNF組(用rmhTNF胸/腹腔內註入治療)和DDP組(用順鉑胸/腹腔內註入治療),觀察兩組療效、生存質量變化及不良反應情況。結果:TNF組總有效率明顯高于DDP組(P<0.05);TNF組生存質量改善率明顯高于DDP組(P<0.05);TNF組的不良反應髮生率明顯低于DDP組。結論:rmhTNF具有顯著的消除胸/腹腔積液的作用,療效明顯優于DDP。
목적:탐토중조개구인종류배사인자( rmhTNF)대악성흉/복강적액적치료작용。방법:관찰56례악성흉/복강적액적환자,수궤분위TNF조(용rmhTNF흉/복강내주입치료)화DDP조(용순박흉/복강내주입치료),관찰량조료효、생존질량변화급불량반응정황。결과:TNF조총유효솔명현고우DDP조(P<0.05);TNF조생존질량개선솔명현고우DDP조(P<0.05);TNF조적불량반응발생솔명현저우DDP조。결론:rmhTNF구유현저적소제흉/복강적액적작용,료효명현우우DDP。
Objective:Toinvestigatetheclinicaleffectandadverseofrecombinanthumantumornecrosisfactor(rmhTNF) for malignant pleural/peritoneal effusion. Methods:Fifty-six patients with malignant pleural/peritoneal effusion were enrolled and randomly divided into two groups. Group TNF was infused with rmhTNF,the another one was infused with cisplatin ( DDP). The effective rate,quality of life and adverse reaction were observed. Results:The total effective rate of TNF group was 89. 3%,while it was 64. 3% in DDP group. There was a significant difference between two groups(P<0. 05). The improve-ment rate of KPS in group TNF was 85. 7%,while it was 56. 7% in DDP group. There was a significant difference between two groups(P<0. 05). The adverse reaction rate of TNF group was significantly smaller than DDP group. Conclusion:The rmhTNF is more effective and response quickly with less adverse reaction for treatment of malignant pleural/peritoneal effusion.